You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

DOLASETRON MESYLATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for dolasetron mesylate and what is the scope of freedom to operate?

Dolasetron mesylate is the generic ingredient in one branded drug marketed by Validus Pharms and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for dolasetron mesylate. One supplier is listed for this compound.

Summary for DOLASETRON MESYLATE
US Patents:0
Tradenames:1
Applicants:1
NDAs:2
Drug Master File Entries: 5
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 185
Clinical Trials: 4
Patent Applications: 5,521
What excipients (inactive ingredients) are in DOLASETRON MESYLATE?DOLASETRON MESYLATE excipients list
DailyMed Link:DOLASETRON MESYLATE at DailyMed
Recent Clinical Trials for DOLASETRON MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Vanderbilt UniversityN/A
University of WashingtonN/A
University of Southern CaliforniaN/A

See all DOLASETRON MESYLATE clinical trials

Pharmacology for DOLASETRON MESYLATE

US Patents and Regulatory Information for DOLASETRON MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-001 Sep 11, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DOLASETRON MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-002 Sep 11, 1997 ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate INJECTABLE;INJECTION 020624-003 Dec 11, 2001 ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-001 Sep 11, 1997 ⤷  Sign Up ⤷  Sign Up
Validus Pharms ANZEMET dolasetron mesylate TABLET;ORAL 020623-002 Sep 11, 1997 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.